Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.35 |
| ▸ | DRD2 | P14416 | 6/20 | 0.34 |
| ▸ | DRD3 | P35462 | 4/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL506152 | 0.87 | ESR1 (0.44) | ESR1ESR2PKMABHD6DRD2 | |
| SCHEMBL507158 | 0.86 | ESR1 (0.44) | ESR1ESR2PKMABHD6DRD2 | |
| SCHEMBL13825293 | 0.86 | ESR1 (0.43) | ESR1ESR2PKMABHD6DRD2 | |
| SCHEMBL506888 | 0.86 | ESR1 (0.43) | ESR1ESR2PKMABHD6DRD2 | |
| SCHEMBL506132 | 0.86 | ESR1 (0.46) | ESR1ESR2PKMABHD6DRD2 | |
| SCHEMBL506487 | 0.86 | ESR1 (0.43) | ESR1ESR2PKMABHD6DRD2 | |
| SCHEMBL10227563 | 0.84 | ESR1 (0.44) | ESR1ESR2PKMABHD6DRD2 | |
| SCHEMBL506389 | 0.84 | ESR1 (0.42) | ESR1ESR2PKMABHD6DRD2 | |
| SCHEMBL507085 | 0.84 | ESR1 (0.53) | ESR1ESR2S1PR5ABHD6ACKR3 | |
| SCHEMBL506848 | 0.84 | ESR1 (0.42) | ESR1ESR2PKMABHD6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580780-B2 | 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist | ELI LILLY AND COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | ELI LILLY AND COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | HTR2C, HTR4, HTR1A | ESR1 311/4885ESR2 319/4885S1PR5 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.